
Amplia Therapeutics Limited (ASX: ATX; OTCQB: INNMF), a pharmaceutical company based in Melbourne, Australia, focuses on development of focal adhesion kinase (FAK) inhibitors for the treatment of cancer and chronic fibrotic diseases. The company's lead product is narmafotinib (AMP945), a best-in-class inhibitor of FAK, currently undergoing clinical trials in advanced pancreatic cancer. Data from the Phase 1b/2a ACCENT trial run in Australia and Korea has been very positive and a new clinical trial is now opening in the US and Australia under an open IND. Additional opportunities in other…
Annual Revenue$1M to $5M
Estimated OwnershipPublicBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.